Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Takeda Pharmaceuticals Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (113)
Cancellation by sponsor (61)
Prescription medicine registration (13)
Australian public assessment report (AusPar) (11)
Designation or determination (5)
Prescription medicine decision summary (3)
Prescription medicine evaluation (3)

Date

2026 (3)
2025 (5)
2024 (31)
2023 (7)
2022 (14)
2021 (14)
2020 (13)
2019 (17)
2018 (6)
2017 (34)
2016 (5)
2015 (5)
2014 (14)
2013 (11)
2012 (3)
2010 (1)
2009 (2)
2008 (8)
2007 (2)
2006 (1)
2005 (9)
2002 (1)
2000 (2)
1999 (1)

Search

Sponsor content

209 result(s) found, displaying 11 to 20

ADCETRIS Takeda Pharmaceuticals Australia Pty Ltd

Jan-2025

Prescription medicine evaluation

Active ingredient: Brentuximab vedotin.
Adzynma Takeda Pharmaceuticals Australia Pty Ltd

Jan-2025

Prescription medicine evaluation

Active ingredient: apadamtase alfa.
FRUZAQLA (Takeda Pharmaceuticals Australia Pty Ltd)

1 October 2024

Prescription medicine registration

Active ingredients: fruquintinib.
OSENI 25/15 25 mg alogliptin (as benzoate) / 15 mg pioglitazone (as hydrochloride) film-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

15 August 2024

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
OSENI 12.5/30 12.5 mg alogliptin (as benzoate) / 30 mg pioglitazone (as hydrochloride) film-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

15 August 2024

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
OSENI 25/30 25 mg alogliptin (as benzoate) / 30 mg pioglitazone (as hydrochloride) film-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

15 August 2024

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
OSENI 25/45 25 mg alogliptin (as benzoate) / 45 mg pioglitazone (as hydrochloride) film-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

15 August 2024

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
OSENI 25/15 25 mg alogliptin (as benzoate) / 15 mg pioglitazone (as hydrochloride) film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

15 August 2024

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
OSENI 25/45 25 mg alogliptin (as benzoate) / 45 mg pioglitazone (as hydrochloride) film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

15 August 2024

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
OSENI 12.5/30 12.5 mg alogliptin (as benzoate) / 30 mg pioglitazone (as hydrochloride) film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

15 August 2024

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd

Pages

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.